liver biopsy specimens from five patients with asymptomatic chronic active hepatitis. One patient had HBV and the other four were "presumed to be cases of non-A, non-B chronic hepatitis".
When Crawford studied "Citation Classics in Hepatopathology" in 2006, the paper by Knodell et al. 1 achieved the highest "number of citations". 2 Thus, the Knodell ''histological activity index'' system (HAI) was proposed and promulgated. The Knodell system evaluated separately, each of four histopathological axes (periportal ± bridging necrosis, intralobular degeneration/focal necrosis, portal inflammation, and "fibrosis"), and assigned a "numerical" score to each. To enhance the discriminant potential of the system, the difference between mild and serious disease was accentuated by eliminating the "number" (category) 2 from the scoring system for each histopathological axis. By omitting "2", the Knodell system allows a "simple" and practical everyday use of the system, by providing a gap between no/insignificant and appreciable/severe visual change for each axis of assessment i.e. 0/1 vs 3/4, (with some additional options for periportal ± bridging necrosis which was thereby given extra weight, because at that time, it was considered the most important determinant of chronic aggressive hepatitis). The score is therefore discontinuous, which has been considered a drawback by some. This objection is redundant when one considers that in any case the numerical labels are not measurements of a continuous variable. A more pernicious fault was the labelling as "fibrosis" of the axis of assessment which subsequently became known as the disease This realisation will help to avoid misunderstandings between histopathologists and clinicians, as well as statistical errors in handling histopathological data. Similarly, the formal acknowledgement of the essential difference between liver fibrosis and liver disease stage, should result in better understanding, and benefits in framing research, and validation of "non invasive markers" of fibrosis. These considerations are relevant to several issues:
Firstly the currently used histological hepatitis scoring systems, which include the Ishak 3 , the METAVIR scoring systems 4 , and other hepatitis scoring systems, use the same principles to describe the "stage" of the liver disease. In all systems the ''stage'' or ''fibrosis'' score comprise a mixture of features. Notably, no individual feature is related specifically to the amount of fibrous tissue in a liver biopsy sample. For example, in the Ishak system the higher scores depend more on the degree of nodularity and on architectural changes, rather than the amount of fibrous tissue.
Secondly these histological staging systems have been misunderstood by many clinicians.
There has been inappropriate use statistically, of the histological stage "scores", which are documented in many publications, including randomized controlled trials. As noted above, histological stage scores describe features that depend on architectural changes and not only on the degree of fibrosis. In addition they are descriptive notations so that, at best, they are ordered categorical data and not numbers. The "number" assigned in the stage score is not a measurement. The "number" is a shorthand label, as explained above, for a morphological A third issue is that a scoring system devised for one particular liver disease is not necessarily applicable to a different aetiology. Thus, a scheme designed for the assessment of 
Histopathological measurement of liver fibrosis
One might argue about the definition of liver fibrosis, but one convenient and widely accepted 9 and to evaluate changes with treatment that affect fibrosis, a precise assessment of the amount of liver fibrosis is required. This can be performed only with a proper measurement of liver collagen.
The amount of collagen can be measured in tissue homogenates using biochemical methods, but this destroys the tissue, without the possibility of obtaining further information from the biopsy, which is unsatisfactory in the assessment of a diagnostic liver biopsy.
Histological evaluation of fibrosis is usually performed using trichrome or reticulin stains.
Each of these stains identify collagen to some extent, but the amount of trichrome or reticulin staining does not necessarily correspond quantitatively with the amount of hepatic collagen. 10 The picroSirius red technique has been shown to be more suitable for quantitative assessment.
Sirius red has an affinity for most hepatic collagens, including types I and III 11, 12 ; and the binding correlates with biochemical hydroxyproline assay under standardized laboratory conditions. 13 The quantity of bound stain also correlates well with biochemically determined collagen content and morphometrically determined hepatic fibrosis, and the method appears to be reliable and reproducible. 14, 15 Thus Sirius red staining is the preferred histochemical method when quantifying liver fibrosis, even though the staining may not be stoichiometric. 11 The routine histopathological analysis of liver biopsies is not compromised by computerassisted digital image analysis of Sirius red stained histological sections; this additional analysis can be performed simply, to measure liver biopsy fibrosis specifically. The evaluation is based on segmentation of digital images to measure the area of collagen, as well as the area of tissue, producing a ''fibrosis ratio'' or proportion of the area of the biopsy occupied by collagen (collagen proportionate area, CPA) 16, 17 . With this technique structural collagen (e.g. blood vessel wall, large septal portal tracts), which is irrelevant to disease processes and other areas that Image analysis studies have evaluated fibrosis in many liver conditions 14, [16] [17] [18] [19] [20] [21] [22] . Published range from 1-7% CPA in normal liver, to 12-36% in cirrhosis. However, the results of these studies are not directly comparable, due to the differences in the technology and methodology used ( Table 1) .
Some of these studies 19, [22] [23] [24] [25] [26] [27] [28] tried to correlate the image analysis measurements (digital image analysis, DIA) of fibrosis with the categorical stage scores, with different results. Manabe et al. 23 found that CPA did not correlate well with the components of the Knodell scoring system. However, the same group later described a more complex scoring system, which correlated with Sirius red staining on the one hand, and Knodell stage scores on the other. 29 The correlation between semiquantitative scoring system and surface density of total collagen was 0.73 (p<0.00001). In the study by Pilette et al. 22 there was a good correlation between the semiquantitative fibrosis score (Knodell and Metavir (modified) scoring systems) and the area of fibrosis (r=0.84, p<0.0001). Kage et al., 19 evaluating the correlation between CPA and a modified stage score, based on the Desmet and Scheuer systems, found that there was a significant correlation in both hepatitis C and B patients (HCV: r=0 .75, p<0.001; HBV: r=0 .67, p<0.001 on the Spearman rank test). In the study by O'Brien et al. 21 a correlation was found between image analysis measurements and Ishak stage score. However it was restricted to biopsy specimens with Ishak stage scores in the range 3 to 6 (Spearman correlation coefficient between stage score and fibrosis ratio was 0.66; p<0.001), whereas among biopsy specimens with Ishak stage scores in the range 0 to 3 it was only 0.14 (p = ns). Although later studies [24] [25] [26] [27] showed good correlations between quantitative morphometric data and Ishak scores of fibrosis, in the study by Maduli et al. 28 the fibrosis ratios observed with morphometry correlated poorly with the Ishak staging Up to now in clinical settings, image analysis has been used infrequently. Four studies have used morphometry to study changes in hepatic fibrosis after alpha interferon therapy. 18, 23, 30, 31 One study has used morphometry to study disease progression in untreated patients with chronic hepatitis C, 19 and one evaluated the fibrosis progression in patients with treatmentrefractory chronic hepatitis C enrolled in a placebo-controlled clinical trial of interferon gamma-1b (IFN-g1b). 32 In the study by Goodman et al. 32 morphometry was found to be a more sensitive tool than histological staging to demonstrate fibrosis progression, because changes in collagen content between baseline and week 48 were more evident than changes in Ishak score. In the study by Fontana et al., 24 the computerized morphometric assessment was evaluated in 386 patients with chronic hepatitis C with an Ishak stage score of at least 3. The relationship between serum markers and quantitative hepatic collagen content was also determined. A significant relationship between hepatic collagen content and the Ishak stage scores was shown (r=48, p<0.0001). There was a weaker relationship with cirrhosis compared to a panel of markers of fibrosis. These studies 24, 32 evaluated patients with either Ishak stage ≥2 32 or Ishak stage ≥3. 24 In these studies the image analysis methodology did not express the amount of collagen as a simple proportionate area (the thickness of the histological section (for which a specialized microscope is needed) was used to calculate the quantity of collagen).
When methodology and study population are (more or less) aligned, the data are more coherent. For example, even though Bedossa et al. 16 Recently Gailhouste et al. 33 proposed a new approach to the analysis of liver fibrosis. This process is based on an application of multiphoton microscopy enabling the observation of unstained samples using endogenous sources of nonlinear signals such as Two-Photon Excitation Fluorescence (TPEF) and Second Harmonic Generation (SHG). They applied this method to 119 biopsies from patients with chronic liver disease showing that this approach allows a measurement of fibrosis that correlates with the "Fibrosis"-Metavir (stage) score (rho = 0.75, p<0.0001). They were able to distinguish patients with Metavir stage F0,1 vs. F2,3,4 (AUROC = 0.88, p<0.0001) and F0,1,2,3 vs. F4 (AUROC = 0.89, p<0.0001).
Relationship between liver disease stage, fibrosis and prognosis
Clinical outcome in chronic progressive liver disease has been related most often to hepatic venous pressure gradient (HVPG), which is a good predictor of survival and decompensation in cirrhotic patients. [34] [35] [36] [37] The clinical application of HVPG measurement has been demonstrated in patients transplanted for HCV liver disease. 38, 39 Also the prognostic value of HVPG has been evaluated in patients with HBV-related cirrhosis treated with lamivudine. 40 One of the first papers which explored the relationship between liver histopathology and In another paper 42 the role of three serum markers (hyaluronic acid, amino-terminal propeptide of type-III procollagen, tissue inhibitor of matrix metalloproteinase type-1) at 3, 6 and 12 months after liver transplantation was examined in 133 liver transplanted patients with HCV recurrence, to evaluate patients at risk of developing significant "fibrosis" and portal hypertension. The AUROC curve of the three serum markers for METAVIR stage F≥2 at 3, 6, and 12 months after transplantation was 0.67, 0.77, and 0.78 respectively. In the group with HVPG ≥ 6mmHg at the same time points, AUROC curves were 0.75, 0.87, and 0.90 respectively, which were significantly better than values obtained with the three previously published scores of "non-invasive makers of liver fibrosis" (AST/ALT ratio 43 Vizzuti et al. 45 compared liver stiffness measurement (LSM) and HVPG in predicting severe portal hypertension in 61 consecutive patients with HCV-related chronic liver disease. A strong relationship between liver stiffness measurement and HVPG measurements was found in the overall population (r = 0.81, P < 0.0001). However, although the correlation was excellent for HVPG values less than 10 or 12mmHg (r = 0.81, P = 0.0003 and r = 0.91, P < 0.0001, kPa and 17.6 kPa, the sensitivity was 97% and 94%, respectively. Carrion et al. 46 evaluated the diagnostic accuracy of LSM to assess the severity of hepatitis C recurrence after liver transplantation in the same cohort studied by Blasco et al.. 39 They found a close direct correlation between liver stiffness and HVPG (Pearson coefficient 0.84; p<0.001) and the AUC for diagnosis of portal hypertension (HVPG≥6 mmHg) was 0.93. In order to discriminate between rapid and slow "fibrosers", the same author 47 The relationship between collagen proportionate area (CPA) and HVPG has been studied by Calvaruso et al. 17 
Histological substaging of cirrhosis by measuring fibrosis
Cirrhosis is defined histologically as "a diffuse process characterized by fibrosis and the conversion of normal liver architecture into structurally abnormal nodules". 7 The word "cirrhosis" has been considered sufficient to describe both a pathological and clinical condition, and to have some prognostic importance, with an implication historically that cirrhosis represents "end stage disease". Nowadays however, the "one-stage description" of cirrhosis has become inadequate, especially considering that better prediction of outcome is needed to provide individualized therapy. 50 In compensated cirrhosis patients with an HVPG <10mmHg have a In their discussion Nagula et al. 54 In any event, regardless of the complexities of variations in septal thickness/nodule size within any given biopsy determined either morphometrically or subjectively, a moments reflection reveals that CPA records the reciprocal balance between nodule size and septal fibrosis: a high CPA will integrate and accurately reflect the overall fibrosis in biopsies with small-ish nodules/thick-ish septa, and conversely a low CPA will characterise biopsies with large-ish nodules/thin-ish septa. In the study by Calvaruso et al. 57 
Conclusion
Since liver disease "stage" was called "fibrosis" by Knodell et al. 1 there has been conflation of the two terms. In the context of chronic liver disease the terms "fibrosis" and "score" should not be contiguous. Liver disease stage definitions include fibrosis, but liver disease stage depends to a great extent on architectural changes as well. Histopathological assignment of liver disease stage is a different process from the measurement of liver fibrosis. The two processes are complementary and each adds value to the liver biopsy assessment. As they are different assessments, the correlation between stage and fibrosis measurement is imperfect. The range of fibrosis (collagen proportionate area, CPA) seen within each liver disease stage represents biological reality, rather than constituting a confusing overlap between stages. The amount of 
